Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples

Table 2 Summary of RT-PCR amplification and sequencing success rate of clinical samples from telaprevir and VX-222 clinical trials

HCV RNA (IU/mL)^a	Genotype/Subtype^b	Numbers of clinical samples	Success rate of RT-PCR amplification % (n/N)	Success rate of sequencing % (n/N)
≥ 1000	1a	5400	97 (5238/5400)	99.6 (5218/5238)
	1b	2400	97 (2328/2400)	99.6 (2318/2328)
100–1000	1a	152	48 (73/152)	98.6 (73/73)
	1b	107	40 (43/107)	100.0 (43/43)

^aHCV RNA was assessed using the Roche TaqMan HCV RNA assay (Version 2.0).
^bGenotype and subtype was defined using 5'NC assay (Trugene) or Versant HCV genotype assay (LiPA) 2.0.

ISSN: 1743-422X